Source:http://linkedlifedata.com/resource/pubmed/id/19597420
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2009-12-23
|
| pubmed:abstractText |
The optimal timing for recombinant human (rh)G-CSF administration after chemotherapy for PBSC mobilization has not yet been determined. In this study, we compared two different time schedules of rhG-CSF; 4th (early) vs 7th day (late), in 48 consecutive patients with multiple myeloma and lymphoma undergoing PBSC mobilization with CE (CY 4 g/m(2) on day 1 and etoposide 200 mg/m(2) on days 1-3). The rhG-CSF dose was 10 microg/kg/day for all patients. Both groups were comparable in terms of sex, age and number of previously given different chemotherapy regimens. Duration of neutropenia, CD34(+) cell count on the first day of apheresis and numbers of aphereses were not statistically different between the two arms. However, the number of doses of rhG-CSF up to the first cycle of apheresis procedures was significantly lower in the late group than in the early group (P=0.005). The median number of total CD34(+) cells collected was 10.54 x 10(6)/kg (range 0.11-37.27) in the early group and 10.81 x 10(6)/kg (range 0.17-49.83) in the late group of rhG-CSF (P=0.781). We conclude that PBSC mobilization after late use of rhG-CSF is an effective approach and therefore, in routine clinical practice, late rhG-CSF may be used for PBSC collections after chemotherapy-based mobilization regimens in this cost-conscious era.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1476-5365
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
44
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
779-83
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:19597420-Adult,
pubmed-meshheading:19597420-Antigens, CD34,
pubmed-meshheading:19597420-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19597420-Female,
pubmed-meshheading:19597420-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:19597420-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:19597420-Humans,
pubmed-meshheading:19597420-Leukapheresis,
pubmed-meshheading:19597420-Lymphoma, Non-Hodgkin,
pubmed-meshheading:19597420-Male,
pubmed-meshheading:19597420-Middle Aged,
pubmed-meshheading:19597420-Multiple Myeloma,
pubmed-meshheading:19597420-Neutropenia,
pubmed-meshheading:19597420-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:19597420-Recombinant Proteins,
pubmed-meshheading:19597420-Time Factors,
pubmed-meshheading:19597420-Transplantation, Autologous
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF.
|
| pubmed:affiliation |
Department of Internal Medicine, Uludag University School of Medicine, Bursa, Turkey.
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study
|